Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $9.33, but opened at $9.91. Arcus Biosciences shares last traded at $9.31, with a volume of 99,569 shares changing hands.
Analysts Set New Price Targets
A number of analysts have weighed in on the company. Wedbush reiterated an "outperform" rating and issued a $33.00 target price on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Barclays decreased their price objective on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. Morgan Stanley dropped their target price on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. The Goldman Sachs Group decreased their price target on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Finally, Wells Fargo & Company dropped their price objective on Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $21.29.
Get Our Latest Analysis on RCUS
Arcus Biosciences Trading Up 1.9%
The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $1.01 billion, a P/E ratio of -2.27 and a beta of 0.80. The company has a 50-day moving average price of $8.87 and a 200 day moving average price of $10.24.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.12). Arcus Biosciences had a negative net margin of 258.94% and a negative return on equity of 70.58%. The firm had revenue of $28.00 million for the quarter, compared to analysts' expectations of $38.61 million. During the same period in the previous year, the company posted ($0.05) earnings per share. The business's quarterly revenue was down 80.7% compared to the same quarter last year. On average, research analysts forecast that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.
Institutional Trading of Arcus Biosciences
A number of institutional investors have recently made changes to their positions in RCUS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Arcus Biosciences by 2.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock valued at $506,000 after buying an additional 833 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Arcus Biosciences by 1.6% in the 2nd quarter. Parallel Advisors LLC now owns 88,007 shares of the company's stock valued at $716,000 after purchasing an additional 1,422 shares during the last quarter. Maryland State Retirement & Pension System boosted its stake in Arcus Biosciences by 10.9% in the 1st quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company's stock worth $159,000 after purchasing an additional 1,986 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Arcus Biosciences by 19.2% during the 4th quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock valued at $223,000 after purchasing an additional 2,410 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in Arcus Biosciences by 8.1% during the 4th quarter. MetLife Investment Management LLC now owns 33,525 shares of the company's stock valued at $499,000 after purchasing an additional 2,521 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.
About Arcus Biosciences
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Further Reading
Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.